Pronai Therapeutics Stock News

HC Wainwright reissued their buy rating on shares of Sierra Oncology (NASDAQ:SRRA) in a research note published on Friday, AnalystRatings.com reports. They currently have a $35.00 price target on the biotechnology company’s stock. Other analysts also recently issued reports about the stock. Cantor Fitzgerald increased their price target on shares of Sierra Oncology from $33.00 […] The post Sierra Oncology’s (SRRA) Buy Rating Reaffirmed at HC Wainwright appeared first on ETF Daily News .

Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today announced data from new retrospective analyses of the Phase 3 SIMPLIFY studies demonstrate baseline ferritin differentially predicts Week 24 Transfusion Independence Response for momelotinib and ruxolitinib in patients with myelofibrosis.

Equities research analysts expect that Sierra Oncology, Inc. (NASDAQ:SRRA) will post ($1.52) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Sierra Oncologys earnings, with estimates ranging from ($1.70) to ($1.27). Sierra Oncology posted earnings per share of ($1.63) in the same quarter last year, which []

Sierra Oncology (NASDAQ:SRRA)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research report issued to clients and investors on Friday, AnalystRatings.com reports. They currently have a $35.00 price target on the biotechnology company’s stock. HC Wainwright’s price target would indicate a potential upside of 49.57% from the stock’s previous […]

SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today announced it will host an analyst and investor event on Thursday, December 16, 2021, at 12:00 pm ET. The event will feature a presentation by Prithviraj Bose, MD, Department of Leukemia, MD Anderson Cancer Center, on the importance of treating anemia in myelofibrosis patients. Dr. Bose will also review

Sierra Oncology (NASDAQ:SRRA) had its price objective raised by Cantor Fitzgerald from $33.00 to $39.00 in a report published on Tuesday morning, The Fly reports. Cantor Fitzgerald currently has an overweight rating on the biotechnology companys stock. Cantor Fitzgerald also issued estimates for Sierra Oncologys FY2022 earnings at ($4.40) EPS. A number of other equities []

Sierra Oncology, Inc. (NASDAQ:SRRA) Cantor Fitzgerald dropped their FY2022 earnings per share estimates for shares of Sierra Oncology in a research report issued to clients and investors on Tuesday, November 30th. Cantor Fitzgerald analyst B. Cheng now forecasts that the biotechnology company will post earnings of ($4.40) per share for the year, down from [] The post Brokers Offer Predictions for Sierra Oncology, Inc.s FY2022 Earnings (NASDAQ:SRRA) appeared first on ETF Daily News .

Sierra Oncology, Inc. (NASDAQ:SRRA) Analysts at Cantor Fitzgerald lowered their FY2022 EPS estimates for Sierra Oncology in a note issued to investors on Tuesday, November 30th. Cantor Fitzgerald analyst B. Cheng now anticipates that the biotechnology company will earn ($4.40) per share for the year, down from their prior estimate of ($4.27). Cantor Fitzgerald []

Sierra Oncology (NASDAQ:SRRA) had its target price hoisted by Cantor Fitzgerald from $33.00 to $39.00 in a research note published on Tuesday, The Fly reports. They currently have an overweight rating on the biotechnology companys stock. SRRA has been the subject of a number of other reports. Zacks Investment Research cut shares of Sierra Oncology []

Sierra Oncology, Inc. (NASDAQ:SRRA) Director Craig A. Collard acquired 5,601 shares of the firm’s stock in a transaction that occurred on Tuesday, November 23rd. The stock was acquired at an average price of $22.95 per share, with a total value of $128,542.95. The transaction was disclosed in a filing with the Securities & Exchange Commission, […]

Sierra Oncology, Inc. (NASDAQ:SRRA) saw a significant decrease in short interest during the month of October. As of October 29th, there was short interest totalling 64,300 shares, a decrease of 15.5% from the October 14th total of 76,100 shares. Based on an average daily volume of 33,800 shares, the short-interest ratio is currently 1.9 days. []

Analysts forecast that Sierra Oncology, Inc. (NASDAQ:SRRA) will announce earnings of ($1.52) per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Sierra Oncologys earnings, with estimates ranging from ($1.70) to ($1.27). Sierra Oncology reported earnings per share of ($1.63) in the same quarter last year, which suggests []

Zacks Investment Research lowered shares of Sierra Oncology (NASDAQ:SRRA) from a hold rating to a sell rating in a report issued on Saturday morning, Zacks.com reports. According to Zacks, Sierra Oncology, Inc. is a clinical-stage drug development company. It develops and markets drugs for the treatment of cancer. The product pipeline consists of SRA737 and []

SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, granted stock optio